Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression

Department of Hematology, Imperial College at Hammersmith Hospital, Du Cane Road, London W12 0NN, UK. BACKGROUND AND OBJECTIVES: The acquisition of additional cytogenetic changes (clonal evolution, CE) during treatment of chronic myeloid leukemia (CML) with imatinib mesylate is currently regarded as...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Haematologica (Roma) 2003-03, Vol.88 (3), p.260-267
Hauptverfasser:	Marktel, S, Marin, D, Foot, N, Szydlo, R, Bua, M, Karadimitris, A, De Melo, VA, Kotzampaltiris, P, Dazzi, F, Rahemtulla, A, Olavarria, E, Apperley, JF, Goldman, JM
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antineoplastic agents Benzamides Biological and medical sciences Chemotherapy Chromosome Aberrations Clone Cells - pathology Cytogenetic Analysis Disease Progression Drug Resistance, Neoplasm - genetics Female Fusion Proteins, bcr-abl - genetics Hematologic and hematopoietic diseases Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged Pharmacology. Drug treatments Piperazines - therapeutic use Prognosis Pyrimidines - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!